抗真菌藥物市場規模、佔有率、趨勢分析報告：2024-2030年按藥物類別、適應症、劑型、配銷通路管道、地區和細分市場預測

Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Polyenes), By Indication (Dermatophytosis, Aspergillosis), By Dosage Form, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

出版日期: 2023年12月22日 | 出版商:

Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

抗真菌藥物市場成長與趨勢：

Grand View Research的最新報告顯示，到2030年，全球抗真菌藥物市場規模預計將達到205.2億美元。

預計2024年至2030年該市場將以3.8%的複合年成長率擴張。全球真菌感染疾病日益流行是推動市場成長的關鍵因素。此外，近年來，由於免疫抑制劑和惡性物、假體裝置和植入物以及廣譜抗生素的使用增加，真菌感染的感染疾病率增加。

根據美國疾病管制與預防中心2017年發布的統計數據，全球每年新發隱球菌腦膜炎感染疾病近22萬例，每年有18.1萬人死亡。由於愛滋病毒/愛滋病的高流行，大多數死亡病例發生在撒哈拉以南非洲地區。這表明由於全球範圍內真菌感染疾病的流行，存在對抗真菌藥物的潛在需求。

許多國家的政府當局已下令在全國範圍內實施封鎖，以遏制 COVID-19 的傳播。同樣，世界各地的衛生系統也在努力維持供應鏈。供應鏈延誤也影響了抗真菌藥物的需求。全球老年人口的成長可能會推動對治療機會性真菌感染疾病的抗真菌藥物的需求，因為老年人更容易受到感染疾病和愛滋病毒和癌症等慢性病的影響。由於難以診斷且死亡率和發病率較高的真菌感染疾病不斷增加，預計到 2030 年，抗真菌藥物的需求將保持強勁。

抗真菌藥物市場報告亮點

Azole類藥物佔市場主導地位，2023年銷售佔有率達47.6%。這一優勢得益於諾沙非、布芬、Diflucan和 Cresemba 等關鍵治療藥物的影響。
由於免疫力缺乏患者的發生率增加和感染復發率高，念珠菌症在 2023 年佔據了最大的市場佔有率。
預計麴菌症在預測期內將出現顯著的複合年成長率。麴菌症是由一種稱為麴菌症的真菌引起的感染疾病，通常會影響呼吸系統。
2023年，口服藥物劑型領導市場。這是因為某些抗真菌藥物被設計為口服給藥以確保適當的吸收。
2023年，醫院藥局將引領市場。醫院藥局在確保即時獲得關鍵藥物方面發揮關鍵作用。醫院藥局提供門診病人和住院服務，促進真菌感染疾病的無縫治療。
北美佔據市場主導地位，2023 年佔 40.9% 的佔有率。該地區的優勢歸因於其高度發展的醫療基礎設施、負擔能力和不斷提高的意識。
預計亞太地區在預測期內將顯著成長。這是由於目標人口龐大、醫療機構開拓新興市場以及主要市場參與者不斷增加的投資。

2023 年及 2030 年區域市場佔有率分析
區域市場儀表板
全球區域市場概況
2018-2030年市場規模及預測趨勢分析：
北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 挪威
- 瑞典
- 丹麥
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 泰國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東/非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 科威特

第9章競爭形勢

主要市場參與企業的最新趨勢和影響分析
公司/競爭分類
供應商形勢
- 主要經銷商及通路夥伴名單
- 主要客戶
- 2023 年主要企業股票分析
- NOVARTIS AG
- PFIZER, INC.
- BAYER AG
- SANOFI
- MERCK &CO., INC.
- F. GSK PLC
- ABBOTT
- GLENMARK
- ASTELLAS PHARMA, INC.
- SCYNEXIS INC.

簡介目錄圖表

Product Code: GVR-1-68038-293-8

Antifungal Drugs Market Growth & Trends:

The global antifungal drugs market size is expected to reach USD 20.52 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.8% from 2024 to 2030. The increasing incidence of fungal infections worldwide is the key factor stoking the growth of the market. In addition, the rise in the adoption of immunosuppressive and antineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics has resulted in an increased incidence of fungal infections in recent years.

According to statistics published by the Centers for Disease Control and Prevention in 2017, it has been estimated that every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths were reported in sub-Saharan Africa, due to the high prevalence of HIV/AIDS. This indicates the potential demand for antifungal drugs due to the high prevalence of mycological infections around the globe.

The government authorities in many countries had ordered nationwide lockdowns in order to contain the spread of COVID-19. Similarly, health systems in a number of countries around the world were having trouble maintaining their supply chains. The slowness of the supply chain has also impacted the demand for antifungal medications. As aged people are more prone to infectious diseases and chronic conditions, including HIV and cancer, the rise in the geriatric population worldwide is likely to stir up the demand for antifungals to treat opportunistic fungal infections. The demand for fungistatic agents is estimated to remain strong through 2030 due to mounting cases of fungal infections that are difficult to diagnose, yielding high mortality and morbidity rates.

Antifungal Drugs Market Report Highlights:

The Azoles drug class segment dominated the market and accounted for a revenue share of 47.6% in 2023. This dominance is attributed to the influence of key therapeutic agents, including noxafil, vfend, diflucan, and cresemba.
The Candidiasis segment held the largest market share in 2023 due to rising incidence of the disease in immunocompromised patients and high rate of recurrent infections.
Aspergillosis is expected to register significant CAGR during the forecast period. Aspergillosis is an infection caused by mold called aspergillosis, which usually affects the respiratory system.
Oral drugs dosage form led the market in 2023. This is attributed to the fact that certain antifungal medications are designed for oral administration to ensure proper ingestion.
Hospital pharmacies led the market in 2023. Hospital pharmacies play a key role in ensuring immediate access to crucial medications. They serve both out-patient and in-patient services, facilitating the seamless treatment of fungal infections.
North America dominated the market and accounted for 40.9% share in 2023. This region dominance is attributed to the highly developed healthcare infrastructure, better affordability, and increasing awareness.
Asia Pacific is anticipated to witness significant growth during the forecast period. This is owing to the presence of large target population, developing healthcare facilities, and increase in investments by leading market players.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Indication
- 1.2.3. Dosage Form
- 1.2.4. Distribution Channel
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
  - 1.4.5.1. Data for primary interviews in North America
  - 1.4.5.2. Data for primary interviews in Europe
  - 1.4.5.3. Data for primary interviews in Asia Pacific
  - 1.4.5.4. Data for primary interviews in Latin America
  - 1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Drug Class outlook
- 2.2.2. Indication outlook
- 2.2.3. Dosage Form outlook
- 2.2.4. Distribution Channel outlook
- 2.2.5. Regional outlook
2.3. Competitive Insights

Chapter 3. Antifungal Drugs Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Increasing Incidence Of Fungal Infections
  - 3.2.1.2. Increase In Awareness
  - 3.2.1.3. Rising R & D Pertaining To The Development Of Novel Drugs
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High Cost Associated With Mrd Testing
  - 3.2.2.2. Complex Regulatory Framework Associated With Mrd Testing
3.3. Antifungal Drugs Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. Antifungal Drugs Market: Drug Class Estimates & Trend Analysis

4.1. Drug Class Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Antifungal Drugs Market by Drug Class Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Azoles
  - 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2. Echinocandins
  - 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.3. Polyenes
  - 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.4. Allylamines
  - 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.5. Others
  - 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antifungal Drugs Market: Indication Estimates & Trend Analysis

5.1. Indication Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Antifungal Drugs Market by Indication Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Dermatophytosis
  - 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Aspergillosis
  - 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Candidiasis
  - 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.4. Others
  - 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Antifungal Drugs Market: Dosage Form Estimates & Trend Analysis

6.1. Dosage Form Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Antifungal Drugs Market by Dosage Form Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.4.1. Oral Drugs
  - 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.2. Ointments
  - 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.3. Powders
  - 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.4. Others
  - 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Antifungal Drugs Market: Distribution Channel Estimates & Trend Analysis

7.1. Distribution Channel Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Antifungal Drugs Market by Distribution Channel Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.4.1. Hospital Pharmacies
  - 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Retails Pharmacies
  - 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. Others
  - 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Antifungal Drugs Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.5. North America
- 8.5.1. U.S.
  - 8.5.1.1. Key country dynamics
  - 8.5.1.2. Regulatory framework/ reimbursement structure
  - 8.5.1.3. Competitive scenario
  - 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.2. Canada
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Regulatory framework/ reimbursement structure
  - 8.5.2.3. Competitive scenario
  - 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Europe
- 8.6.1. UK
  - 8.6.1.1. Key country dynamics
  - 8.6.1.2. Regulatory framework/ reimbursement structure
  - 8.6.1.3. Competitive scenario
  - 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.2. Germany
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Regulatory framework/ reimbursement structure
  - 8.6.2.3. Competitive scenario
  - 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.3. France
  - 8.6.3.1. Key country dynamics
  - 8.6.3.2. Regulatory framework/ reimbursement structure
  - 8.6.3.3. Competitive scenario
  - 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.4. Italy
  - 8.6.4.1. Key country dynamics
  - 8.6.4.2. Regulatory framework/ reimbursement structure
  - 8.6.4.3. Competitive scenario
  - 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.5. Spain
  - 8.6.5.1. Key country dynamics
  - 8.6.5.2. Regulatory framework/ reimbursement structure
  - 8.6.5.3. Competitive scenario
  - 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.6. Norway
  - 8.6.6.1. Key country dynamics
  - 8.6.6.2. Regulatory framework/ reimbursement structure
  - 8.6.6.3. Competitive scenario
  - 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.7. Sweden
  - 8.6.7.1. Key country dynamics
  - 8.6.7.2. Regulatory framework/ reimbursement structure
  - 8.6.7.3. Competitive scenario
  - 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.8. Denmark
  - 8.6.8.1. Key country dynamics
  - 8.6.8.2. Regulatory framework/ reimbursement structure
  - 8.6.8.3. Competitive scenario
  - 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.7. Asia Pacific
- 8.7.1. Japan
  - 8.7.1.1. Key country dynamics
  - 8.7.1.2. Regulatory framework/ reimbursement structure
  - 8.7.1.3. Competitive scenario
  - 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.2. China
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Regulatory framework/ reimbursement structure
  - 8.7.2.3. Competitive scenario
  - 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.3. India
  - 8.7.3.1. Key country dynamics
  - 8.7.3.2. Regulatory framework/ reimbursement structure
  - 8.7.3.3. Competitive scenario
  - 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.4. Australia
  - 8.7.4.1. Key country dynamics
  - 8.7.4.2. Regulatory framework/ reimbursement structure
  - 8.7.4.3. Competitive scenario
  - 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.5. South Korea
  - 8.7.5.1. Key country dynamics
  - 8.7.5.2. Regulatory framework/ reimbursement structure
  - 8.7.5.3. Competitive scenario
  - 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.6. Thailand
  - 8.7.6.1. Key country dynamics
  - 8.7.6.2. Regulatory framework/ reimbursement structure
  - 8.7.6.3. Competitive scenario
  - 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.8. Latin America
- 8.8.1. Brazil
  - 8.8.1.1. Key country dynamics
  - 8.8.1.2. Regulatory framework/ reimbursement structure
  - 8.8.1.3. Competitive scenario
  - 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.2. Mexico
  - 8.8.2.1. Key country dynamics
  - 8.8.2.2. Regulatory framework/ reimbursement structure
  - 8.8.2.3. Competitive scenario
  - 8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.3. Argentina
  - 8.8.3.1. Key country dynamics
  - 8.8.3.2. Regulatory framework/ reimbursement structure
  - 8.8.3.3. Competitive scenario
  - 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.9. MEA
- 8.9.1. South Africa
  - 8.9.1.1. Key country dynamics
  - 8.9.1.2. Regulatory framework/ reimbursement structure
  - 8.9.1.3. Competitive scenario
  - 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.2. Saudi Arabia
  - 8.9.2.1. Key country dynamics
  - 8.9.2.2. Regulatory framework/ reimbursement structure
  - 8.9.2.3. Competitive scenario
  - 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.3. UAE
  - 8.9.3.1. Key country dynamics
  - 8.9.3.2. Regulatory framework/ reimbursement structure
  - 8.9.3.3. Competitive scenario
  - 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.4. Kuwait
  - 8.9.4.1. Key country dynamics
  - 8.9.4.2. Regulatory framework/ reimbursement structure
  - 8.9.4.3. Competitive scenario
  - 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
- 9.3.1. List of key distributors and channel partners
- 9.3.2. Key customers
- 9.3.3. Key company market share analysis, 2023
- 9.3.4. NOVARTIS AG
  - 9.3.4.1. Company overview
  - 9.3.4.2. Financial performance
  - 9.3.4.3. Product benchmarking
  - 9.3.4.4. Strategic initiatives
- 9.3.5. PFIZER, INC.
  - 9.3.5.1. Company overview
  - 9.3.5.2. Financial performance
  - 9.3.5.3. Product benchmarking
  - 9.3.5.4. Strategic initiatives
- 9.3.6. BAYER AG
  - 9.3.6.1. Company overview
  - 9.3.6.2. Financial performance
  - 9.3.6.3. Product benchmarking
  - 9.3.6.4. Strategic initiatives
- 9.3.7. SANOFI
  - 9.3.7.1. Company overview
  - 9.3.7.2. Financial performance
  - 9.3.7.3. Product benchmarking
  - 9.3.7.4. Strategic initiatives
- 9.3.8. MERCK & CO., INC.
  - 9.3.8.1. Company overview
  - 9.3.8.2. Financial performance
  - 9.3.8.3. Product benchmarking
  - 9.3.8.4. Strategic initiatives
- 9.3.9. F. GSK PLC
  - 9.3.9.1. Company overview
  - 9.3.9.2. Financial performance
  - 9.3.9.3. Product benchmarking
  - 9.3.9.4. Strategic initiatives
- 9.3.10. ABBOTT
  - 9.3.10.1. Company overview
  - 9.3.10.2. Financial performance
  - 9.3.10.3. Product benchmarking
  - 9.3.10.4. Strategic initiatives
- 9.3.11. GLENMARK
  - 9.3.11.1. Company overview
  - 9.3.11.2. Financial performance
  - 9.3.11.3. Product benchmarking
  - 9.3.11.4. Strategic initiatives
- 9.3.12. ASTELLAS PHARMA, INC.
  - 9.3.12.1. Company overview
  - 9.3.12.2. Financial performance
  - 9.3.12.3. Product benchmarking
  - 9.3.12.4. Strategic initiatives
- 9.3.13. SCYNEXIS INC.
  - 9.3.13.1. Company overview
  - 9.3.13.2. Financial performance
  - 9.3.13.3. Product benchmarking
  - 9.3.13.4. Strategic initiatives

簡介目錄圖表

List of Tables

Table 1 List of abbreviation
Table 2 North America antifungal drugs market, by region, 2018 - 2030 (USD Million)
Table 3 North America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 4 North America antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 5 North America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 6 North America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 7 U.S. antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 8 U.S. antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 9 U.S. antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 10 U.S. antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 11 Canada antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 12 Canada antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 13 Canada antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 14 Canada antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 15 Europe antifungal drugs market, by region, 2018 - 2030 (USD Million)
Table 16 Europe antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 17 Europe antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 18 Europe antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 19 Europe antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 20 Germany antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 21 Germany antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 22 Germany antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 23 Germany antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 24 UK antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 25 UK antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 26 UK antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 27 UK antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 France antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 29 France antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 30 France antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 31 France antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 32 Italy antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 33 Italy antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 34 Italy antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 35 Italy antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 36 Spain antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 37 Spain antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 38 Spain antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 39 Spain antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Denmark antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 41 Denmark antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 42 Denmark antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 43 Denmark antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 44 Sweden antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 45 Sweden antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 46 Sweden antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 47 Sweden antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 48 Norway antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 49 Norway antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 50 Norway antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 51 Norway antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 52 Asia Pacific antifungal drugs market, by region, 2018 - 2030 (USD Million)
Table 53 Asia Pacific antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 54 Asia Pacific antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 55 Asia Pacific antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 56 Asia Pacific antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 57 China antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 58 China antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 59 China antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 60 China antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 61 Japan antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 62 Japan antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 63 Japan antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 64 Japan antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 65 India antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 66 India antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 67 India antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 68 India antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 69 South Korea antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 70 South Korea antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 71 South Korea antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 72 South Korea antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 73 Australia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 74 Australia antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 75 Australia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 76 Australia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 77 Thailand antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 78 Thailand antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 79 Thailand antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 80 Thailand antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 81 Latin America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 82 Latin America antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 83 Latin America antifungal drugs market, by application, 2018 - 2030 (USD Million)
Table 84 Latin America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 85 Latin America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 86 Brazil antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 87 Brazil antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 88 Brazil antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 89 Brazil antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 90 Mexico antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 91 Mexico antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 92 Mexico antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 93 Mexico antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 94 Argentina antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 95 Argentina antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 96 Argentina antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 97 Argentina antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 98 MEA antifungal drugs market, by region, 2018 - 2030 (USD Million)
Table 99 MEA antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 100 MEA antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 101 MEA antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 102 MEA antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 103 South Africa antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 104 South Africa antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 105 South Africa antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 106 South Africa antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 111 UAE antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 112 UAE antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 113 UAE antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 114 UAE antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 115 Kuwait antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
Table 116 Kuwait antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
Table 117 Kuwait antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
Table 118 Kuwait antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)